Are women with major depression in pregnancy identifiable in population health data?

BMC Pregnancy and Childbirth

Carol Bower²  Fiona J Stanley³  Linda Slack-Smith¹  Lyn Colvin¹ 

[1] School of Dentistry, The University of Western Australia, Perth, Australia;Western Australian Register of Developmental Anomalies, Perth, Australia;Telethon Institute for Child Health Research, Centre for Child Health Research, The University of Western Australia, Perth, Australia

关键词: Antidepressant;    Pregnancy;    Depression;    Case ascertainment;    Pharmacovigilance;    Data linkage;    Population-based;   

Others  :  1138148
DOI  :  10.1186/1471-2393-13-63

 received in 2012-11-08, accepted in 2013-03-07,  发布年份 2013

【 摘 要 】

Background

Although record linkage of routinely collected health datasets is a valuable research resource, most datasets are established for administrative purposes and not for health outcomes research. In order for meaningful results to be extrapolated to specific populations, the limitations of the data and linkage methodology need to be investigated and clarified. It is the objective of this study to investigate the differences in ascertainment which may arise between a hospital admission dataset and a dispensing claims dataset, using major depression in pregnancy as an example. The safe use of antidepressants in pregnancy is an ongoing issue for clinicians with around 10% of pregnant women suffer from depression. As the birth admission will be the first admission to hospital during their pregnancy for most women, their use of antidepressants, or their depressive condition, may not be revealed to the attending hospital clinicians. This may result in adverse outcomes for the mother and infant.

Methods

Population-based de-identified data were provided from the Western Australian Data Linkage System linking the administrative health records of women with a delivery to related records from the Midwives’ Notification System, the Hospital Morbidity Data System and the national Pharmaceutical Benefits Scheme dataset. The women with depression during their pregnancy were ascertained in two ways: women with dispensing records relating to dispensed antidepressant medicines with an WHO ATC code to the 3rd level, pharmacological subgroup, ‘N06A Antidepressants’; and, women with any hospital admission during pregnancy, including the birth admission, if a comorbidity was recorded relating to depression.

Results

From 2002 to 2005, there were 96698 births in WA. At least one antidepressant was dispensed to 4485 (4.6%) pregnant women. There were 3010 (3.1%) women with a comorbidity related to depression recorded on their delivery admission, or other admission to hospital during pregnancy. There were a total of 7495 pregnancies identified by either set of records. Using data linkage, we determined that these records represented 6596 individual pregnancies. Only 899 pregnancies were found in both groups (13.6% of all cases). 80% of women dispensed an antidepressant did not have depression recorded as a comorbidity on their hospital records. A simple capture-recapture calculation suggests the prevalence of depression in this population of pregnant women to be around 16%.

Conclusion

No single data source is likely to provide a complete health profile for an individual. For women with depression in pregnancy and dispensed antidepressants, the hospital admission data do not adequately capture all cases.

【 授权许可】

   
2013 Colvin et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Alessandri LM, Chambers HM, Garfield C, Vukovich S, Read AW: Cumulative mortality in children aged 1 to 6 years born in Western Australia from 1980–89. Arch Dis Child 1999, 80(1):15-20.
• [2]Brameld KJ, Holman CD, Bass AJ, Codde JP, Rouse IL: Hospitalisation of the elderly during the last year of life: an application of record linkage in Western Australia 1985–1994. J Epidemiol Community Health 1998, 52(11):740-744.
• [3]Hansen M, Kurinczuk JJ, Bower C, Webb S: The risk of major birth defects after intracytoplasmic sperm injection and in vitro fertilization. N Engl J Med 2002, 346(10):725-730.
• [4]Spilsbury K, Semmens JB, Saunders CM, Hall SE, Holman CD: Subsequent surgery after initial breast conserving surgery: a population based study. ANZ J Surg 2005, 75(5):260-264.
• [5]Holman CD, Bass AJ, Rosman DL, Smith MB, Semmens JB, Glasson EJ, Brook EL, Trutwein B, Rouse IL, Watson CR: A decade of data linkage in Western Australia: strategic design, applications and benefits of the WA data linkage system. Aust Health Rev 2008, 32(4):766-777.
• [6]Australian Institute of Health and Welfare: Mental health services in Australia 2007–08. Canberra: AIHW; 2010.
• [7]Australian Institute of Health and Welfare: Mental health services in Australia 2006–07. Canberra: AIHW; 2009.
• [8]Australian Institute of Health and Welfare: Mental health services - in brief. Canberra: AIHW; 2011.
• [9]Buist A, Bilszta J: The beyondblue National Postnatal Screening Program, Prevention and Early Intervention 2001–2005, Final Report. Vol 1: National Screening Program. Melbourne: beyondblue: the national depression initiative; 2006.
• [10]National Centre for Classification in Health: International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM). Sydney: National Centre for Classification in Health; 1999.
• [11]Colvin L, Slack-Smith L, Stanley FJ, Bower C: Pharmacovigilance in pregnancy using population-based linked datasets. Pharmacoepidemiol Drug Saf 2009, 18(3):211-225.
• [12]Colvin L, Slack-Smith L, Stanley FJ, Bower C: Linking a pharmaceutical claims database with a birth defects registry to investigate birth defect rates of suspected teratogens. Pharmacoepidemiol Drug Saf 2010, 19(11):1137-1150.
• [13]Data and Modelling Section, Pharmaceutical Policy and Analysis Branch: PBS Expenditure and Prescriptions Twelve Months to 30 June 2006. Canberra: Commonwealth Department of Health and Ageing; 2006.
• [14]Malm H, Martikainen J, Klaukka T, Neuvonen PJ: Prescription of hazardous drugs during pregnancy. Drug Saf 2004, 27(12):899-908.
• [15]Prescribing medicines in pregnancy: an Australian categorisation of risk of drug use in pregnancy. 4th ed. http://www.tga.gov.au/hp/medicines-pregnancy.htm webcite
• [16]Department of Health Western Australia: Hospital Morbdiity Data System Reference Manual July 2004. Perth: Health Data Collections Branch, Health Information Centre; 2004.
• [17]Private Mental Health Alliance: Private Hospital-based Psychiatric Services 1 July 2010 to 30 June 2011. In National Model for the Collection and Analysis of a Minimum Data Set with Outcome Measures for Private Hospital-based Psychiatric Services. Canberra: Centralised Data Management Service; 2012.
• [18]National Collaborating Centre for Mental Health: Depression: the treatment and management of depression in adults (updated edition). Commissioned by the National Institute for Health and Clinical Excellence. National Clinical Practice Guideline 90. London: The British Psychological Society and The Royal College of Psychiatrists; 2010.
• [19]Australian Bureau of Statistics: Socio-Economic Indexes for Areas (SEIFA) - Technical Paper 2006. In Information Paper 2001 Census of Population and Housing. Canberra: Commonwealth of Australia; 2008.
• [20]Automatch. Matchware Technologies Inc Kennebunk, ME, USA;
• [21]Holman CD, Bass AJ, Rouse IL, Hobbs MS: Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health 1999, 23(5):453-459.
• [22]Stanley FJ, Croft ML, Gibbins J, Read AW: A population database for maternal and child health research in Western Australia using record linkage. Paediatr Perinat Epidemiol 1994, 8(4):433-447.
• [23]Giles GG: Medical record linkage in Australia: this is as good as it gets. ANZ J Surg 2005, 75(5):259.
• [24]SAS/STAT: Copyright © 2009 by SAS Institute Inc. Cary, NC, USA;
• [25]LaPorte RE, McCarty DJ, Tull ES, Tajima N: Counting birds, bees, and NCDs. Lancet 1992, 339(8791):494-495.
• [26]Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, Ramin S, Chaudron L, Lockwood C: The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009, 31(5):403-413.
• [27]Hall P: Current considerations of the effects of untreated maternal perinatal depression and the National Perinatal Depression Initiative. J Dev Orig Health Dis 2012, 3(4):293-295.
• [28]Johanson R, Chapman G, Murray D, Johnson I, Cox J: The North Staffordshire Maternity Hospital prospective study of pregnancy-associated depression. J Psychosom Obstet Gynaecol 2000, 21(2):93-97.
• [29]Austin MP: Antenatal screening and early intervention for “perinatal” distress, depression and anxiety: where to from here? Arch Womens Ment Health 2004, 7(1):1-6.
• [30]Pereira AT, Bos SC, Marques M, Maia BR, Soares MJ, Valente J, Gomes AA, Macedo A, de Azevedo MH: The postpartum depression screening scale: is it valid to screen for antenatal depression? Arch Womens Ment Health 2011, 14(3):227-238.
• [31]Adverse Drug Reactions Advisory Committee: Maternal SSRI use and neonatal effects. Aust Adverse Drug React Bull 2003, 22(4):14.
• [32]Nordeng H, Spigset O: Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy: effects on the infant. Drug Saf 2005, 28(7):565-581.
• [33]Field T: Prenatal depression and selective serotonin reuptake inhibitors. Int J Neurosci 2010, 120(3):163-167.
• [34]Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL: Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005, 293(19):2372-2383.
• [35]Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL: Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996, 335(14):1010-1015.
• [36]Field T, Diego M, Hernandez-Reif M: Prenatal depression effects on the fetus and newborn: a review. Infant Behav Dev 2006, 29(3):445-455.
• [37]Austin MP, Highet N, and the Guidelines Expert Advisory Committee: Clinical practice guidelines for depression and related disorders – anxiety, bipolar disorder and puerperal psychosis – in the perinatal period. A guideline for primary care health professionals. Melbourne: beyondblue: the national depression initiative; 2011.
• [38]Cox JL, Holden JM, Sagovsky R: Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry 1987, 150:782-786.
• [39]Colvin L, Slack-Smith L, Stanley FJ, Bower C: Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A Clin Mol Teratol 2011, 91(3):142-152.
• [40]Pharmaceutical Benefits Scheme News Updates. http://www.pbs.gov.au/info/healthpro/explanatory-notes webcite
• [41]Morton AP: A to X: the problem of categorisation of drugs in pregnancy - an Australian perspective. Med J Aust 2012, 196(3):172-173.
• [42]Kelman CW, Pearson SA, Day RO, Holman CD, Kliewer EV, Henry DA: Evaluating medicines: let's use all the evidence. Med J Aust 2007, 186(5):249-252.
• [43]Stergachis AS: Record linkage studies for postmarketing drug surveillance: data quality and validity considerations. Drug Intell Clin Pharm 1988, 22(2):157-161.
• [44]Libby G, MacDonald TM, Evans JM: Record-linkage methodology for prescribing research. J Clin Pharm Ther 2001, 26(4):241-246.